MAM
TBPH icon

Martingale Asset Management’s Theravance Biopharma TBPH Stock Holding History

Martingale Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
105,500
+39,574
+60% +$655K 0.04% 411
2026
Q1 		$1.07M Sell
65,926
-532
-0.8% -$9.41K 0.03% 479
2025
Q4 		$1.24M Sell
66,458
-4,508
-6% -$74.8K 0.03% 428
2025
Q3 		$1.04M Buy
70,966
+2,125
+3% +$26.9K 0.03% 468
2025
Q2 		$759K Buy
68,841
+7,511
+12% +$73K 0.02% 526
2025
Q1 		$548K Buy
61,330
+2,680
+5% +$24.9K 0.01% 583
2024
Q4 		$552K Buy
58,650
+4,200
+8% +$38.2K 0.01% 586
2024
Q3 		$439K Buy
54,450
+6,870
+14% +$59.5K 0.01% 654
2024
Q2 		$403K Buy
47,580
+16
+0% +$144 0.01% 645
2024
Q1 		$427K Sell
47,564
-1,100
-2% -$10.2K 0.01% 643
2023
Q4 		$547K Sell
48,664
-30,020
-38% -$302K 0.01% 592
2023
Q3 		$679K Hold
78,684
– – 0.01% 542
2023
Q2 		$814K Buy
78,684
+1,901
+2% +$21K 0.02% 500
2023
Q1 		$833K Buy
76,783
+16,041
+26% +$170K 0.02% 490
2022
Q4 		$682K Buy
+60,742
New +$638K 0.01% 565
2020
Q4 		– Sell
-11,200
Closed -$166K – 1038
2020
Q3 		$166K Buy
11,200
+1,400
+14% +$26.2K ﹤0.01% 987
2020
Q2 		$206K Buy
+9,800
New +$252K ﹤0.01% 989

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Martingale Asset Management's TBPH Position: Q2 2026 in Review

Martingale Asset Management increased its Theravance Biopharma (TBPH) stake by 60% in Q2 2026, buying an estimated $655K and bringing the position to 105,500 shares worth $1.79M. The position accounts for 0.04% of the portfolio, ranked #411.

Martingale Asset Management first reported a position in TBPH in Q2 2020 and has held it in 17 quarters since. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Martingale Asset Management held 105,500 shares of Theravance Biopharma worth $1.79M as of Q2 2026.
  • Martingale Asset Management bought 39,574 Theravance Biopharma shares in Q2 2026, an estimated $655K.
  • Theravance Biopharma made up 0.04% of Martingale Asset Management's portfolio in Q2 2026, its #411 holding.
  • Martingale Asset Management first reported a position in Theravance Biopharma in Q2 2020 and has held it in 17 quarters since.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.